Novartis AG ADR (NVS)vsP3 Health Partners Inc (PIII)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
PIII
P3 Health Partners Inc
$2.77
-1.07%
HEALTHCARE · Cap: $588.18M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3778% more annual revenue ($56.58B vs $1.46B). NVS leads profitability with a 23.9% profit margin vs -10.1%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PIII
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Intrinsic value data unavailable for PIII.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
3.8% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -6953.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PIII
PIII has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : PIII
The primary concerns for PIII are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a declining stock while PIII is a turnaround play — different risk/reward profiles.
PIII carries more volatility with a beta of 0.56 — expect wider price swings.
PIII is growing revenue faster at 3.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 34/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →P3 Health Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
P3 Health Partners Inc (PIII) is a forward-thinking healthcare organization that focuses on improving care quality and reducing costs through innovative, data-driven strategies. Utilizing advanced analytics and telehealth technologies, P3 delivers personalized care to underserved populations while maintaining a comprehensive network of primary care providers and specialists. As a pioneer in value-based care models, the company collaborates with community partners to address the increasing demand for efficient healthcare solutions. With its commitment to high-quality, cost-effective care, PII is strategically positioned to excel in the dynamic healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?